Research ArticleIMMUNOLOGY
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti–PD-1/PD-L1 immunotherapy
- View ORCID ProfileMuhammad Zaeem Noman1,
- View ORCID ProfileSantiago Parpal2,3,
- Kris Van Moer1,
- View ORCID ProfileMalina Xiao1,
- View ORCID ProfileYasmin Yu2,3,
- Tsolere Arakelian1,
- View ORCID ProfileJenny Viklund2,
- View ORCID ProfileAngelo De Milito2,3,
- Meriem Hasmim1,
- Martin Andersson2,
- Ravi K. Amaravadi4,
- View ORCID ProfileJessica Martinsson2,
- View ORCID ProfileGuy Berchem1,5,* and
- View ORCID ProfileBassam Janji1,*,†
- 1Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
- 2Sprint Bioscience, Stockholm, Sweden.
- 3Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden.
- 4Department of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
- 5Department of Hemato-Oncology, Centre Hospitalier du Luxembourg, Luxembourg City, Luxembourg.
- ↵†Corresponding author. Email: bassam.janji{at}lih.lu
↵* Co-senior authors.
See allHide authors and affiliations
Science Advances 29 Apr 2020:
Vol. 6, no. 18, eaax7881
DOI: 10.1126/sciadv.aax7881
Vol. 6, no. 18, eaax7881
DOI: 10.1126/sciadv.aax7881
Muhammad Zaeem Noman
1Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Santiago Parpal
2Sprint Bioscience, Stockholm, Sweden.
3Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden.
Kris Van Moer
1Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Malina Xiao
1Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Yasmin Yu
2Sprint Bioscience, Stockholm, Sweden.
3Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden.
Tsolere Arakelian
1Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Jenny Viklund
2Sprint Bioscience, Stockholm, Sweden.
Angelo De Milito
2Sprint Bioscience, Stockholm, Sweden.
3Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden.
Meriem Hasmim
1Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
Martin Andersson
2Sprint Bioscience, Stockholm, Sweden.
Ravi K. Amaravadi
4Department of Medicine and Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Jessica Martinsson
2Sprint Bioscience, Stockholm, Sweden.
Guy Berchem
1Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
5Department of Hemato-Oncology, Centre Hospitalier du Luxembourg, Luxembourg City, Luxembourg.
Bassam Janji
1Tumor Immunotherapy and Microenvironment Group, Department of Oncology, Luxembourg Institute of Health (LIH), Luxembourg City, Luxembourg.
